Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2022

Share-Based Payment Arrangement [Abstract]

Fair Value of Options Estimated on Date of Grant Using Black-Scholes Option Pricing Model

Under the 2019 Plan, the fair value of the Baudax Bio options was estimated on the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions:

	June 30,
	2021
Expected option life	5.5 years
Expected volatility	75.37%
Risk-free interest rate	0.78%
Expected dividend yield		—

Summary of Stock Option Activity

The following table summarizes Baudax Bio stock option activity during the six months ended June 30, 2022:

	Number of shares			Weighted average exercise price		Weighted average remaining contractual life
Balance, December 31, 2021		125,418		$	76.05	8.6 years
Expired/forfeited/cancelled		(35,756	)	$	49.85
Balance, June 30, 2022		89,662		$	86.50	7.6 years
Vested		61,610		$	85.63	7.1 years
Vested and expected to vest		89,662		$	86.50	7.6 years

Summary of RSUs Activity

The following table summarizes Baudax Bio RSUs activity during the six months ended June 30, 2022:

	Number of shares			Weighted average grant date fair value
Balance, December 31, 2021		41,069		$	63.79
Granted		501,209			0.76
Vested and settled		(11,337	)		44.77
Expired/forfeited/cancelled		(7,023	)		57.22
Balance, June 30, 2022		523,918		$	3.99
Expected to vest		508,792